Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Abecma | — | 2021-08-18 | europa.eu ↗ |
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07544589 | Apr 2026 → Apr 2046 expected | colorectal cancer, esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal adenocarcinoma | Dispatch Biotherapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT04855136 | Jun 2021 → Apr 2025 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT04196491 | May 2020 → Jun 2023 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02658929 | Dec 2015 → Jul 2019 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05393804 | May 2022 → May 2027 expected | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05032820 | Jan 2022 → Aug 2024 | plasma cell myeloma | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 2 | NCT03642626 | Dec 2018 → Feb 2024 overdue | acute lymphoblastic leukemia, large B-cell lymphoma | Masonic Cancer Center, University of Minnesota | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03601078 | Dec 2018 → Jan 2026 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 2 | NCT03361748 | Dec 2017 → Dec 2023 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06045806 | Oct 2023 → Aug 2025 overdue | plasma cell myeloma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03651128 | Apr 2019 → Apr 2026 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04771078 | — | plasma cell myeloma | Celgene Corporation | Available | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | idecabtagene vicleucel | “Idecabtagene vicleucel (ide-cel; bb2121) is a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T cell therapy approved for treatment of patients with heavily...” PMID 36794354 ↗ Feb 20234“Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy” PMID 36762851 ↗ Feb 2023 “idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor” NCT07544589 ↗ |
| Known as | Abecma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03642626 ↗ |
| Known as | Anti-bcma car t cell | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298199 ↗ |
| Known as | bb2121 | “A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant” NCT05393804 ↗ |
| Known as | Ide-Cel | “Idecabtagene vicleucel (ide-cel; bb2121) is a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T cell therapy approved for treatment of patients with heavily...” PMID 36794354 ↗ Feb 20235“Idecabtagene vicleucel (ide-cel) is a chimeric antigen receptor (CAR) T-cell therapy approved for relapsed and refractory multiple myeloma (RRMM).” PMID 41894689 ↗ Jun 2026 “A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant” NCT05393804 ↗ “Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy” PMID 36762851 ↗ Feb 2023 “idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor” NCT07544589 ↗ |
| Known as | Idecabtagen vicleucel | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298199 ↗ |
| Modality | Cell therapy | “bb2121 chimeric antigen receptor (CAR) modified T cells” NCT03361748 ↗ |
| Route | Other | “bb2121 autologous CAR T cells will be infused” NCT02658929 ↗ |
| Target | TNFRSF17 | “Tumor necrosis factor receptor superfamily member 17 binding agent” CHEMBL4298199 ↗ |